Menu Search
Equities

Esperion Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0IIM:LSE

Esperion Therapeutics Inc

Actions
  • Price (USD)3.35
  • Today's Change0.055 / 1.67%
  • Shares traded152.95k
  • 1 Year change+80.11%
  • Beta1.1074
Data delayed at least 20 minutes, as of Feb 10 2026 18:58 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

  • Revenue in USD (TTM)303.80m
  • Net income in USD-105.83m
  • Incorporated2008
  • Employees304.00
  • Location
    Esperion Therapeutics Inc3891 Ranchero DriveSuite 150, Suite 300ANN ARBOR 32960United StatesUSA
  • Phone+1 (734) 887-3903
  • Fax+1 (302) 655-5049
  • Websitehttps://www.esperion.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.